Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Cameron Turtle
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 125
- Beta
- 3.00
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 66.79
Financials
Revenue
$0.00-100.0%Net Income
$-36.20MEBITDA
$-36.20MFree Cash Flow
$-69.88MEPS (diluted)
$-0.36Shares Outstanding (diluted)
84.73M+15795.4%Operating Expenses
$81.64MCash & Debt
$1.15BReturn of Capital
$0.00Revenue by Segment (annual)
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-155.20M | $-1.98 |
| 2024 | $0.00 | $-208.02M | $-3.18 |
| 2023 | $886.0K | $-338.79M | $-46.15 |
| 2022 | $2.33M | $-83.81M | $-24.86 |
| 2021 | $18.74M | $-65.80M | $-25.02 |
| 2020 | $0.00 | $-80.89M | $-37.89 |
| 2019 | $0.00 | $-78.25M | $-61.23 |
| 2018 | $3.89M | $-44.35M | $-53.25 |
| 2017 | $5.21M | $-27.24M | $-45.01 |
| 2016 | $4.63M | $-21.70M | $-55.40 |
| 2015 | $6.08M | $-11.29M | $-24.71 |
| 2014 | $0.00 | $-10.35M | $-18.91 |
Valuation
SYREhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
137+173.33%Social Signal Score
Mentions (18)
- News (RSS)investing·12h ago·Neutral
Why is Spyre Therapeutics stock sliding today?
View source ↗ - Newsglobenewswire.com·14h ago·Negative
…cing of $350.0 Million Public Offering of Common Stock WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced the pricing of its previously announced underwritten public offering…
View source ↗ - Newsglobenewswire.com·18h ago·Negative
…Announces Proposed Public Offering of its Common Stock WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that it has commenced an underwritten public offering of its common …
View source ↗ - Newsdefenseworld.net·2d ago·Neutral
Spyre (NASDAQ: SYRE) legal chief trims stake in planned share sale What happened Spyre Therapeutics, Inc. (NASDAQ: SYRE) Chief Legal Officer and Corporate Secretary Heidy King-Jones sold 28,933 shares on 2026-10-01. The Form 4 shows five sale blocks at weighted-average prices from $89.24 to $93.46 per share, totaling about $2.63 million. It also shows a separate 28,933-share option exercise at $14.5 per share, and the filing
View source ↗ - Newsglobenewswire.com·3d ago·Neutral
Spyre Therapeutics Announces Grants of Inducement Awards WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre's independent Compensation Committee of the Board of Di…
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newszacks.com·26d ago·Neutral
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study SYRE's SPY003 posts positive phase II UC data, strengthening Spyre's multi-mechanism IBD strategy.
View source ↗ - Newsglobenewswire.com·31d ago·Neutral
Spyre Therapeutics Announces Grants of Inducement Awards WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre's independent Compensation Committee of the Board of D…
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
Spyre Therapeutics to Participate in Upcoming September Investor Conferences WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that management will participate in the following upcoming investor conf…
View source ↗ - Newszacks.com·32d ago·Neutral
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound? Spyre Therapeutics (SYRE) reported earnings 30 days ago. What's next for the stock?
View source ↗ - News (RSS)yahoo·40d ago·Negative
Spyre Therapeutics Plunges; Why Analysts Aren't Sweating
View source ↗ - Newszacks.com·40d ago·Neutral
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis Spyre's SPY072 shows activity in RA, but a smaller-than-expected benefit shifts its focus toward broader autoimmune uses and combinations.
View source ↗ - News (RSS)zerohedge·40d ago·Neutral
…ins 7% as UBS upgrades to buy, saying the solar company is positioned for market-share gains following the FCC ban on new inverter model imports. Spyre Therapeutics (SYRE) sinks 11% after the drug developer said a mid-stage trial of its experimental drug for rheumatoid arthritis, an autoimmune disease, fell short of the company’s internal bar to develop it as a monotherapy. Summit Therapeutics (SMMT) rises 8% after the cancer drug developer gave results from a late-stage trial of its experimenta…
View source ↗ - Newsglobenewswire.com·41d ago·Negative
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072 Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (e.g., ACR50)
View source ↗ - Newszacks.com·42d ago·Positive
Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk? Spyre has a broad clinical pipeline and cash runway, but elevated valuation makes upcoming readouts critical to its investment case.
View source ↗ - Newszacks.com·42d ago·Neutral
SYRE Rallies 44.9% in 3 Months. Can Clinical Catalysts Sustain It? Spyre's 2026 clinical catalysts and positive ulcerative colitis data fuel momentum, but its lofty valuation raises the stakes for upcoming readouts.
View source ↗ - News (RSS)venturebeat·42d ago·Neutral
IBM’s next-gen mainframe chip is the first to run Arm and Z workloads on the same cores IBM is announcing today at the annual Hot Chips conference what may be the most consequential change to mainframe architecture in decades: a processor whose cores can natively execute both IBM's own instruction set and Arm's — switching between the two in nanoseconds.The chip, which will power the next generation of IBM Z and LinuxONE systems, is the first dual-architecture mainframe processor ever built. It
View source ↗ - News (RSS)investing·48d ago·Neutral
Spyre Therapeutics stock hits 52-week high at 108.16 USD
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $-0.78 per share
Typical surprise +11.9% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-0.36 vs $-0.76beat
- Tue, May 5$-0.74 vs $-0.66miss
- Thu, Feb 19$-0.70 vs $-0.66miss
- Tue, Nov 4$-0.15 vs $-0.76beat
- Tue, Aug 5$-0.49 vs $-0.73beat
- Thu, May 8$-0.74 vs $-0.84beat
Estimates and results for SYRE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SYRE officers and directors.
- Bought
- —
- Sold
- $430.7m
0 trades
64 trades
- King-jones Heidysold
- King-jones Heidysold
- King-jones Heidysold
- King-jones Heidysold
- King-jones Heidysold
- Turtle Cameronsold
- Turtle Cameronsold
- Turtle Cameronsold
36 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SYRE.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.